LOXL4 drives radiotherapy resistance and immunosuppression in glioma by targeting SOCS3 for degradation to activate STAT3 signaling
International Immunopharmacology · 2026-08 · 182 · 116784
DOI: 10.1016/j.intimp.2026.116784 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-08. Verfasst von Guo Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. Hauptthemen laut MEDLINE: Glioma, STAT3 Transcription Factor, Radiation Tolerance, Suppressor of Cytokine Signaling 3 Protein. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Radiotherapy (RT) resistance in glioma is closely linked to abnormal JAK/STAT signaling, but its upstream drivers are unclear. This study investigates the role of lysyl oxidase-like 4 (LOXL4) in this process. METHODS: LOXL4 expression and its correlation with prognosis and immune infiltration were analyzed using TCGA and CGGA datasets. Stable RT-resistant glioma cell models were established. The functional role of LOXL4 in DNA repair, apoptosis, and pathway activity was assessed. Molecular mechanisms were explored via co-immunoprecipitation (Co-IP) and mass spectrometry. A brain-targeted LOXL4 siRNA nanodelivery system was developed and evaluated in an orthotopic glioma mouse model combined with RT. RESULTS: LOXL4 is upregulated in high-grade glioma and RT-resistant patients, correlating with poor survival. Mechanistically, LOXL4 promotes the ubiquitination and degradation of suppressor of cytokine signaling 3 (SOCS3). This relieves SOCS3-mediated inhibition of JAK2, leading to sustained STAT3 activation. Consequently, this axis enhances DNA damage repair, inhibits apoptosis, and fosters an immunosuppressive tumor microenvironment. The brain-targeted LOXL4 siRNA nanodelivery system synergized with RT, significantly prolonging survival in glioma-bearing mice. CONCLUSION: LOXL4 acts as a novel upstream regulator of the JAK/STAT pathway by degrading SOCS3, driving RT resistance and immune remodeling in glioma. Targeting the LOXL4-SOCS3-STAT3 axis with a nanodelivery system presents a promising radiosensitization strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
- Department of Radiology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Neurosurgery, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
- Department of Neurosurgery, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China. Electronic address: 956577530@qq.com.
- Department of Neurology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China. Electronic address: yangzhao5140@sohu.com.
Zitieren
APA
Du, G., Ding, Z., Hou, J., Su, Q., Li, Q., Xia, X., & Yang, Z. (2026). LOXL4 drives radiotherapy resistance and immunosuppression in glioma by targeting SOCS3 for degradation to activate STAT3 signaling. International Immunopharmacology, 182, 116784. https://doi.org/10.1016/j.intimp.2026.116784
Vancouver
Du G, Ding Z, Hou J, Su Q, Li Q, Xia X, et al. LOXL4 drives radiotherapy resistance and immunosuppression in glioma by targeting SOCS3 for degradation to activate STAT3 signaling. International Immunopharmacology. 2026;182:116784. doi:10.1016/j.intimp.2026.116784
BibTeX
@article{Du2026,
author = {Du, Guo and Ding, Zhaojun and Hou, Jianxun and Su, Qiuyu and Li, Qinhong and Xia, Xiaohui and Yang, Zhao},
title = {LOXL4 drives radiotherapy resistance and immunosuppression in glioma by targeting SOCS3 for degradation to activate STAT3 signaling},
journal = {International Immunopharmacology},
year = {2026},
volume = {182},
pages = {116784},
doi = {10.1016/j.intimp.2026.116784}
}
EUVIMED